Christina Cooper, MD
Family Medicine · El Dorado, ARNPI 1194166199
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Medtronic at 58.1% of the total. Reporting peaked in 2020 at $958 and has fallen 78.2% since, to $209 in 2025.
Across 226 payments — averaging $13.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Astellas Pharma US Inc$386
- Novo Nordisk$239
- AbbVie$176
- Amgen$81
- Pfizer$73
- plus $340 from 12 others
What the payments were for
- Food & beverage$3,093100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 144 | $1,798 |
| Astellas Pharma US Inc | 26 | $386 |
| Novo Nordisk | 13 | $239 |
| AbbVie | 9 | $176 |
| Amgen | 6 | $81 |
| Pfizer | 4 | $73 |
| GSK | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 4 | $49 |
| Genentech USA, Inc. | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Boston Scientific | 2 | $32 |
| Novartis | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Bristol Myers Squibb | 2 | $23 |
| Lilly USA, LLC | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Johnson & Johnson | 1 | $11 |
How this compares
$3,093 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 21 | $153,593 |
| OzempicSemaglutide | 77 | $89,187 |
| EliquisApixaban | 151 | $61,045 |
| JardianceEmpagliflozin | 110 | $60,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $47,036 |
| JanuviaSitagliptin Phosphate | 49 | $37,752 |
| TrulicityDulaglutide | 39 | $35,413 |
| MounjaroTirzepatide | 32 | $35,074 |
| OxycontinOxycodone Hcl | 12 | $34,164 |
| XareltoRivaroxaban | 57 | $25,728 |
| LinzessLinaclotide | 34 | $25,336 |
| FarxigaDapagliflozin Propanediol | 51 | $23,849 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $21,351 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 83 | $18,263 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $16,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $239 | $89,18777 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arexvy | $49 | $87,608195 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $12 | $70,48771 claims |
| PfizerEliquis | $73 | $61,045151 claims |
| AbbVieLinzess, Lumigan, Synthroid | $176 | $34,639101 claims |
| Johnson & JohnsonXarelto | $11 | $25,72857 claims |
| NovartisEntresto | $31 | $12,99342 claims |
| Astellas Pharma US IncMyrbetriq | $386 | $7,82225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in El Dorado
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Broderick EatonWynne$49K
- Craig LevoyBentonville$30K
- Allen BeachyFort Smith$21K
- Hunter CarringtonHot Springs$20K
- Harold BettonLittle Rock$18K
- Thad HardinConway$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.